Berberine and Omega-3 Composition for IBD Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for inflammatory bowel disease (IBD) are suboptimal, with limited effectiveness and significant side effects, necessitating the development of novel therapeutic approaches.
Innovation Solution
The use of berberine or its derivatives in combination with omega-3 fatty acids, such as eicosapentaenoic acid and docosahexaenoic acid, to create pharmaceutical compositions that can be administered to treat IBD, reducing inflammation and promoting mucosal healing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anti-inflammatory and immunosuppressive drugs are used to treat IBD, then inflammation is interrupted, but the therapeutic effect is limited and adverse side effects occur
Solution Approach 1:
The patent combines berberine and omega-3 fatty acids into a single pharmaceutical composition to achieve synergistic anti-inflammatory effects. This merging of two distinct therapeutic agents addresses the limited effectiveness of single-drug therapies while the synergistic interaction aims to reduce the required dosage of each component, thereby minimizing adverse side effects.
Solution Approach 2:
The invention creates a composite therapeutic formulation consisting of berberine and omega-3 fatty acids. This composite approach leverages the complementary mechanisms of action between the two components - berberine's anti-inflammatory and immunomodulatory properties combined with omega-3's role in resolving inflammation - to achieve superior therapeutic effectiveness while reducing individual component dosages and associated side effects.
2Reliability
If berberine and omega-3 fatty acids are combined in a pharmaceutical composition, then bioavailability is improved and side effects are reduced, but the formulation complexity increases
Solution Approach 1:
The patent merges berberine and omega-3 fatty acids into a single integrated pharmaceutical composition. This combination improves bioavailability through synergistic absorption mechanisms while the unified formulation structure manages complexity by presenting both components in one dosage form rather than requiring separate administration.
Data Source
AI summary
The invention provides novel pharmaceutical compositions of berberine or a derivative or analog of berberine, or a salt thereof, in combination with one or more omega-3 fatty acids or esters thereof, and methods of their use in treating inflammatory bowel disease.